Development of a novel transdermal patch of alendronate, a nitrogen‐containing bisphosphonate, for the treatment of osteoporosis

Bisphosphonates are widely used for the treatment and prevention of bone diseases, including Paget disease, hypercalcemia of malignancy, and postmenopausal osteoporosis. In this study, we developed a novel transdermal patch of alendronate, a nitrogen‐containing bisphosphonate, for the treatment of bone diseases. The maximum permeation fluxes of alendronate through rat and human skin after application of this patch were 1.9 and 0.3 µg/cm2 per hour, respectively. The bioavailability (BA) of alendronate in rats was approximately 8.3% after the application of alendronate patch and approximately 1.7% after oral administration. These results indicated that the transdermal permeation of alendronate using this patch system was sufficient for the treatment of bone diseases. The plasma calcium level was effectively reduced after application of the alendronate patch in 1α‐hydroxyvitamin D3–induced hypercalcemia model rats. The alendronate patch also effectively suppressed the decrease in bone mass in model rats with osteoporosis. Modest alendronate‐induced erythema of rat skin was observed after application of the alendronate patch. Incorporation of butylhydroxytoluene in the alendronate patch almost completely suppressed this alendronate‐induced skin damage while maintaining the transdermal permeation and pharmacologic effects of alendronate. These findings indicate that our novel transdermal delivery system for alendronate is a promising approach to improve compliance and quality of life of patients in the treatment of bone diseases. © 2010 American Society for Bone and Mineral Research.

[1]  B. Clarke,et al.  Bisphosphonates: mechanism of action and role in clinical practice. , 2008, Mayo Clinic proceedings.

[2]  R. Russell,et al.  Bisphosphonates: Mode of Action and Pharmacology , 2007, Pediatrics.

[3]  H. Gwak,et al.  The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin. , 2008, International journal of pharmaceutics.

[4]  P. L. Bergsagel,et al.  Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. , 2006, Mayo Clinic proceedings.

[5]  G. Rodan,et al.  Bisphosphonate mechanism of action , 2002, Current molecular medicine.

[6]  K. Nakatsuka.  [Development of bisphosphonates]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[7]  G. Rodan,et al.  In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. , 2000, Endocrinology.

[8]  John H. Draize,et al.  METHODS FOR THE STUDY OF IRRITATION AND TOXICITY OF SUBSTANCES APPLIED TOPICALLY TO THE SKIN AND MUCOUS MEMBRANES , 1944 .

[9]  R. Scheuplein,et al.  Percutaneous absorption of steroids. , 1969, The Journal of investigative dermatology.

[10]  P. Eggli,et al.  Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat , 1986, Calcified Tissue International.

[11]  M. Atabek,et al.  Oral Alendronate Therapy for Severe Vitamin D Intoxication of the Infant with Nephrocalcinosis , 2006, Journal of pediatric endocrinology & metabolism : JPEM.

[12]  K. Broadley,et al.  Systematic review of bisphosphonates for hypercalcaemia of malignancy , 2004, Palliative medicine.

[13]  B. Ozkan,et al.  Intragastric alendronate therapy in two infants with vitamin D intoxication: A new method , 2008, Clinical toxicology.

[14]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[15]  R. Guy,et al.  Uptake of two zwitterionic surfactants into human skin in vivo. , 1993, Toxicology and applied pharmacology.

[16]  Y. Hayami,et al.  Alendronate-induced esophagitis: possible pathogenic role of hypersensitivity to alendronate. , 2008, Internal medicine.

[17]  J. Iwamoto,et al.  Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients , 2009, Journal of Bone and Mineral Metabolism.

[18]  C. Löwik,et al.  Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. , 2003, Bone.

[19]  Ş. Çetinel,et al.  Gastroprotective effect of leukotriene receptor blocker montelukast in alendronat-induced lesions of the rat gastric mucosa. , 2005, Prostaglandins, Leukotrienes and Essential Fatty Acids.

[20]  W. Sterry,et al.  Follicular Penetration: Development of a Method to Block the Follicles Selectively against the Penetration of Topically Applied Substances , 2006, Skin Pharmacology and Physiology.

[21]  P. Fine,et al.  Toxic acute tubular necrosis following treatment with zoledronate (Zometa). , 2003, Kidney international.

[22]  M. Sato,et al.  Effects of bisphosphonates on isolated Rat osteoclasts as examined by reflected light microscopy , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  T Yano,et al.  Skin permeability of various non-steroidal anti-inflammatory drugs in man. , 1986, Life sciences.

[24]  G. Golomb,et al.  Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. , 2000, Advanced drug delivery reviews.

[25]  H. Fleisch.  Experimental basis for the use of bisphosphonates in Paget's disease of bone. , 1987, Clinical orthopaedics and related research.

[26]  H. Kikkawa,et al.  Analysis of Change Patterns of Microcomputed Tomography 3-Dimensional Bone Parameters as a High-Throughput Tool to Evaluate Antiosteoporotic Effects of Agents at an Early Stage of Ovariectomy-Induced Osteoporosis in Mice , 2006, Investigative radiology.

[27]  Ş. Çetinel,et al.  Octreotide ameliorates alendronate-induced gastric injury , 2004, Peptides.

[28]  H. Fleisch.  The role of bisphosphonates in breast cancer: Development of bisphosphonates , 2001, Breast Cancer Research.

[29]  D. Graham.  REVIEW: What the Gastroenterologist Should Know About the Gastrointestinal Safety Profiles of Bisphosphonates , 2002, Digestive Diseases and Sciences.

[30]  B. Gertz,et al.  Pharmacokinetics of Alendronate , 1999, Clinical pharmacokinetics.

[31]  P. Acott,et al.  Determination of pamidronate in human whole blood and urine by reversed-phase HPLC with fluorescence detection. , 2004, Biomedical chromatography : BMC.

[32]  M. Rogers,et al.  Inhibition of Protein Prenylation by Bisphosphonates Causes Sustained Activation of Rac, Cdc42, and Rho GTPases , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  M. S. Brewer,et al.  Effect of natural and synthetic antioxidants on the oxidative stability of cooked, frozen pork patties. , 2009, Journal of food science.

[34]  S. Yalkowsky,et al.  Correlation and prediction of mass transport across membranes. I. Influence of alkyl chain length on flux-determining properties of barrier and diffusant. , 1972, Journal of pharmaceutical sciences.

[35]  P. Vandenabeele,et al.  Butylated hydroxyanisole is more than a reactive oxygen species scavenger , 2006, Cell Death and Differentiation.

[36]  B. Mazières,et al.  Topical Ketoprofen Patch (100 mg) for the Treatment of Ankle Sprain: A Randomized, Double-Blind, Placebo-Controlled Study , 2005, The American journal of sports medicine.

[37]  Özer Şehirli,et al.  Protective effect of taurine against alendronate‐induced gastric damage in rats , 2005, Fundamental & clinical pharmacology.

[38]  Nobuhiro Ozawa,et al.  Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate , 2007, Journal of Bone and Mineral Metabolism.

[39]  Y. Azuma,et al.  Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. , 1995, Bone.

[40]  R. Bronaugh,et al.  Methods for in vitro percutaneous absorption studies. II. Animal models for human skin. , 1982, Toxicology and applied pharmacology.